Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

49.1K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.1K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

6.8K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
6.8K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.1K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

1.8K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Laparoscopic <i>versus</i> open liver resection following transarterial radioembolization for hepatocellular carcinoma: a retrospective propensity score-matched study.

Annals of surgical treatment and research·2026
Same author

Robotic left lateral sectionectomy using the Hugo™ Robotic-Assisted Surgery system: a case report.

International journal of surgery case reports·2026
Same author

Hepatic Congestion-linked Intrahepatic Biliary Strictures After Living Donor Liver Transplantation.

Transplantation·2026
Same author

Definition and Classification of Minimally Invasive Major Hepatectomy (MIMH): A Literature Review and Expert Survey in the Fifth World Congress of the International Laparoscopic Liver Surgery (ILLS).

Annals of surgery open : perspectives of surgical history, education, and clinical approaches·2026
Same author

Anatomical risk stratification for major portal vein complications in dual portal vein living donor liver transplantation: a retrospective cohort study.

Annals of surgical treatment and research·2026
Same author

Risk Factors for Postoperative Hyperbilirubinemia in Living Donors Undergoing Living Donor Liver Transplantation.

Clinical transplantation·2026

Related Experiment Video

Updated: Jan 5, 2026

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

7.1K

Antiviral therapy may decrease HBx, affecting cccDNA and MSL2 in hepatocarcinogenesis.

Xue-Li Jin1, Suk Kyun Hong1, Hwajung Kim1

  • 1Department of Surgery, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.

Oncology Letters
|October 16, 2019
PubMed
Summary
This summary is machine-generated.

Chronic hepatitis B virus (HBV) infection drives liver cancer. This study found covalently closed circular DNA (cccDNA) and MSL2 are elevated in tumors, and antiviral therapy reduces viral protein HBx, inhibiting cancer growth.

Keywords:
covalently closed circular DNAhepatitis Bhepatitis B virus-encoded X proteinhepatocellular carcinomamale specific lethal 2

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.4K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K

Related Experiment Videos

Last Updated: Jan 5, 2026

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

7.1K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.4K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K

Area of Science:

  • Hepatology
  • Oncology
  • Virology

Background:

  • Chronic hepatitis B virus (HBV) is a primary cause of hepatocellular carcinoma (HCC).
  • Covalently closed circular DNA (cccDNA) is a key HBV replication intermediate.
  • HBV-encoded X protein (HBx) is a viral oncoprotein implicated in tumor development.

Purpose of the Study:

  • To compare levels of cccDNA, MSL2 mRNA, and HBx mRNA in tumor versus peri-tumor tissues in HBV-associated HCC patients.
  • To evaluate the impact of antiviral therapy on these molecular indicators.
  • To elucidate the role of cccDNA and MSL2 in HBV-associated HCC tumorigenesis.

Main Methods:

  • Quantitative PCR was used to measure intrahepatic cccDNA, MSL2 mRNA, and HBx mRNA levels.
  • Analysis was performed on tumor and peri-tumor tissues from 50 HBV-associated HCC patients.
  • Patient data included preoperative antiviral treatment status and presence of cirrhosis.

Main Results:

  • Intrahepatic cccDNA levels were significantly higher in tumor tissues than peri-tumor tissues (P=0.001).
  • Higher cccDNA and MSL2 mRNA levels were observed in tumor tissues of patients with cirrhosis (P<0.001 and P=0.023, respectively).
  • Antiviral therapy significantly reduced HBx mRNA levels in both tumor and peri-tumor tissues (P=0.026 and P=0.035).

Conclusions:

  • cccDNA plays a significant role in the tumorigenesis of HBV-associated HCC.
  • Antiviral therapy may modulate hepatocarcinogenesis by reducing HBx levels, thereby inhibiting the oncogenic effects of MSL2 and cccDNA.
  • MSL2 facilitates HBx ubiquitylation, upregulating its activity and promoting tumor growth.